Mirum Pharmaceuticals to Acquire Bluejay Therapeutics in $620M Deal, Expanding Rare Disease Focus

Mirum Pharmaceuticals, a rare disease company, has entered a definitive agreement to acquire privately held Bluejay Therapeutics, adding worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV). The transaction strengthens Mirum’s rare liver disease portfolio and adds a fourth potential registrational milestone within the next 18 months.

Brelovitug is currently being evaluated in the global AZURE Phase 3 program for HDV, the most severe form of viral hepatitis, with top-line data expected in the second half of 2026 and a potential biologics license application and launch targeted for 2027. In Phase 2 studies, the therapy demonstrated complete viral response alongside improved liver enzymes and a favorable safety profile. HDV affects patients already infected...

Today's Sponsors

Today's Sponsor